Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dave Singh

Showing results (421-430 of 505) with videos related to

Pageof 51
Sort By:
The Lancet. Respiratory Medicine|December 9, 2024
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trialDave Singh, Christopher E Brightling, Klaus F Rabe, et al.
The Lancet. Respiratory Medicine|February 3, 2025
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Breathe (Sheffield, England)|June 28, 2023
Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022Daiana Stolz, Maria Gabriella Matera, Paola Rogliani, et al.
American Journal of Respiratory and Critical Care Medicine|June 5, 2018
A Disintegrin and A Metalloproteinase-9 (ADAM9): A Novel Proteinase Culprit with Multifarious Contributions to COPDXiaoyun Wang, Francesca Polverino, Joselyn Rojas-Quintero, et al.
Respiratory Medicine|March 2, 2025
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scoresClaus F Vogelmeier, Klaus F Rabe, Surya P Bhatt, et al.
Respiratory Medicine|October 31, 2024
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)Surya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The Journal of Allergy and Clinical Immunology|January 14, 2026
First-in-human study for londamocitinib (AZD4604), an inhaled, selective JAK1 inhibitorTina Jellesmark Jensen, Camille Riff, Julia Lund, et al.
JAMA Internal Medicine|September 23, 2016
Azithromycin for Acute Exacerbations of Asthma : The AZALEA Randomized Clinical TrialSebastian L Johnston, Matyas Szigeti, Mary Cross, et al.
ERJ Open Research|March 15, 2021
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysisMeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
The European Respiratory Journal|December 14, 2022
Development of a tool to detect small airways dysfunction in asthma clinical practiceJanwillem Kocks, Thys van der Molen, Jaco Voorham, et al.
Pageof 51

Showing results (421-430 of 505) with videos related to

Sort By:
Pageof 51
The Lancet. Respiratory Medicine|December 9, 2024
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trialDave Singh, Christopher E Brightling, Klaus F Rabe, et al.
The Lancet. Respiratory Medicine|February 3, 2025
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Breathe (Sheffield, England)|June 28, 2023
Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022Daiana Stolz, Maria Gabriella Matera, Paola Rogliani, et al.
American Journal of Respiratory and Critical Care Medicine|June 5, 2018
A Disintegrin and A Metalloproteinase-9 (ADAM9): A Novel Proteinase Culprit with Multifarious Contributions to COPDXiaoyun Wang, Francesca Polverino, Joselyn Rojas-Quintero, et al.
Respiratory Medicine|March 2, 2025
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scoresClaus F Vogelmeier, Klaus F Rabe, Surya P Bhatt, et al.
Respiratory Medicine|October 31, 2024
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)Surya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The Journal of Allergy and Clinical Immunology|January 14, 2026
First-in-human study for londamocitinib (AZD4604), an inhaled, selective JAK1 inhibitorTina Jellesmark Jensen, Camille Riff, Julia Lund, et al.
JAMA Internal Medicine|September 23, 2016
Azithromycin for Acute Exacerbations of Asthma : The AZALEA Randomized Clinical TrialSebastian L Johnston, Matyas Szigeti, Mary Cross, et al.
ERJ Open Research|March 15, 2021
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysisMeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
The European Respiratory Journal|December 14, 2022
Development of a tool to detect small airways dysfunction in asthma clinical practiceJanwillem Kocks, Thys van der Molen, Jaco Voorham, et al.
Pageof 51